Your browser doesn't support javascript.
loading
More rapid bone mineral density loss in older men with diabetes: The Osteoporotic Fractures in Men (MrOS) Study.
Tramontana, Flavia; Napoli, Nicola; Litwack-Harrison, Stephanie; Bauer, Douglas C; Orwoll, Eric S; Cauley, Jane A; Strotmeyer, Elsa S; Schwartz, Ann V.
Affiliation
  • Tramontana F; Operative Research Unit of Osteo-Metabolic and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Napoli N; Research Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy.
  • Litwack-Harrison S; Operative Research Unit of Osteo-Metabolic and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Bauer DC; Research Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, Rome, Italy.
  • Orwoll ES; California Pacific Medical Center Research Institute, San Francisco, CA, USA.
  • Cauley JA; Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
  • Strotmeyer ES; Oregon Health & Science University, Portland, OR, USA.
  • Schwartz AV; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Article de En | MEDLINE | ID: mdl-38407631
ABSTRACT
CONTEXT Type 2 diabetes mellitus (T2D) is associated with more rapid bone loss in women, but less evidence is available for men or those with prediabetes.

OBJECTIVE:

To determine whether bone loss rate is affected by diabetes status in older men, we analyzed data from the Osteoporotic Fractures in Men (MrOS) study.

METHODS:

The multisite MrOS study enrolled 5,994 men aged ≥65 years. Diabetes status was defined by self-report, diabetes medication use, or elevated fasting serum glucose at baseline. Hip bone mineral density (BMD) was measured by dual energy x-ray absorptiometry (DXA) at baseline and a follow-up visit after 4.6 ± 0.4 years. This analysis included 4095 men, excluding those without a follow-up DXA or with unknown diabetes status. Changes in hip BMD in participants with normoglycemia (NG), prediabetes, or T2D, excluding thiazolidinedione (TZD) users, were evaluated using generalized linear models (GLM). Diabetes medication use and BMD loss among those with T2D were also evaluated with GLM.

RESULTS:

In adjusted models, loss in hip BMD was greater in men with T2D (- 2.23% 95% CI -2.54 to -1.91; p<0.001) but not in men with prediabetes (-1.45%; 95% CI -1.63 to -1.26; p=0.33) compared to NG (-1.57% 95% CI -1.73 to -1.41). Among men with T2D, TZD, insulin and sulfonylurea use were associated with greater hip BMD loss.

CONCLUSIONS:

Men with T2D, but not prediabetes, experienced an accelerated bone loss compared to participants with normoglycemia. More rapid bone loss predicts increased risk of fractures and mortality in broader populations.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: J Clin Endocrinol Metab Année: 2024 Type de document: Article Pays d'affiliation: Italie Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: J Clin Endocrinol Metab Année: 2024 Type de document: Article Pays d'affiliation: Italie Pays de publication: États-Unis d'Amérique